Patel Sushil 4
4 · Revolution Medicines, Inc. · Filed Nov 4, 2024
Insider Transaction Report
Form 4
Patel Sushil
Director
Transactions
- Exercise/Conversion
Common Stock
2024-10-31$24.84/sh+5,000$124,200→ 24,948 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-31−5,000→ 13,400 totalExercise: $24.84From: 2024-06-08Exp: 2033-06-07→ Common Stock (5,000 underlying) - Sale
Common Stock
2024-10-31$54.14/sh−5,000$270,715→ 19,948 total
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on September 7, 2023.
- [F2]Includes 7,748 restricted stock units.
- [F3]The transaction was executed in multiple trades in prices ranging from $54.00 to $54.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.